Drugs mediating myocardial protection

European Journal of Anaesthesiology

Volumn 26, Issue 12, 2009, Pages 985-995

  De Hert, Stefan G ^a   Preckel, Benedikt ^a   Hollmann, Markus W ^a   Schlack, Wolfgang S ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Myocardial ischaemia; Myocardial reperfusion injury; Outcome; Pharmacological treatment; Postconditioning; Preconditioning

Indexed keywords

ADENOSINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CORTICOSTEROID DERIVATIVE; DESFLURANE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENFLURANE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHALATION ANESTHETIC AGENT; INSULIN; ISOFLURANE; METOPROLOL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MORPHINE; NITRATE; NITRIC OXIDE; POTASSIUM; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SEVOFLURANE; ANESTHETIC AGENT; CALCIUM; OXYGEN;

BRADYCARDIA; CALCIUM HOMEOSTASIS; CELL DEATH; COLLATERAL CIRCULATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY THROMBOSIS; ENERGY METABOLISM; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HUMAN; HYPOTENSION; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; REPERFUSION INJURY; REVIEW; STROKE; METABOLISM; METHODOLOGY;

ANESTHETICS; CALCIUM; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; OXYGEN; REACTIVE OXYGEN SPECIES;

EID: 77449085867     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e32832fad8b     Document Type: Review

References (158)

1. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300.
2. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-1912.
3. + exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart. Cardiovasc Res 2000;48:244-253.
4. Wang Q-D, Pernow J, Sjö quist P-O, Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 2002;55:25-37.
5. Piper HM, Meuter K, Schä fer C. Cellular mechanisms of ischemiareperfusion injury. Ann Thorac Surg 2003;75:S644-S648.
6. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003;93:292-301.
7. Piper HM, Abdallah Y, Schäfer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004;61:365-371.
8. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497.
9. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005;14:170-175.
10. Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci 2005;1047:248-258.
11. Honda HM, Ping P. Mitochondrial permeability transition in cardiac cell injury and death. Cardiovasc Drug Ther 2006;20:425-432.
12. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007; 75:530-535.
13. Liem DA, Honda HM, Zhang J, et al. Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol 2007;103:2129-2136.
14. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713-1720.
15. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-1794.
16. Schouten O, Bax JJ, Dunkelgrun M, et al. Pro: beta-blockers are indicated for patients at risk for cardiac complications undergoing noncardiac surgery. Anesth Analg 2007;104:8-10.
17. Brady AR, Gibbs JS, Greenhalgh RM,et al. Peri-operative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery. Results of a randomized double-blind controlled trial. J Vasc Surg 2005;41:602-609.
18. Devereaux PJ, Beattie WS, Choi PTL, et al. How strong is the evidence for the use of perioperative β-blockers in noncardiac surgery? Systematic reviews and meta-analysis of randomised controlled trials. BMJ 2005;331:313-321.
19. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative β-blockade in patients with diabetes undergoing major noncardiac surgery: randomized, placebo-controlled, blinded, multicenter trial. BMJ 2006;332:1482-1488
20. Yang H, Raymer K, Butler R, et al. The effects of perioperative betablockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006;152:983-990.
21. POISE study group. Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial): a randomized controlled trial. Lancet 2008;371:1839-1847.
22. Bangalore S, Wetterslev J, Pranesh S, et al. Perioperative b-blockers in patients having noncardiac surgery: a meta-analysis. Lancet 2008;372:1962-1976.
23. Stevens RD, Burri H, Tramer MR. Pharmacological myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesth Analg 2003;97:623-633.
24. Slogoff S, Keats AS. Does chronic treatment with calcium entry blocking drugs reduce perioperative myocardial ischemia? Anesthesiology 1998;68:676-680.
25. Nishina K, Mikawa K, Uesugi T, et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 2002;96:323-329.
26. Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 2003;114:742-752.
27. Miller TD, Christian TF, Hopfenspirger MR, et al. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-341.
28. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical implications. Curr Probl Cardiol 1994;19:59-113.
29. Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res 1997;33:243-257.
30. Ferrari R, Pepi P, Ferrari F, et al. Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol 1998;82:K2-K13.
31. Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998;82:K14-K17.
32. Taegtmeyer H, King LM, Jones B. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 1998;82:K54-K60.
33. Lee L, Horowitz J, FrenneauxM.Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-641.
34. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003;41:1404-1407.
35. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-1156.
36. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction: the ECLA Collaborative Group. Circulation 1998;98:2227-2234.
37. Apstein CS, Opie LH. Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drug Ther 1999;13:185-190.
38. Ceremuzynski L, Budaj A, Czepiel A, et al. Low-dose glucose- insulinpotassium is ineffective in acute myocardial infarction: results of a randomized muticenter Pol-GIK trial. Cardiovasc Drugs Ther 1999;13:191-200.
39. van der Horst ICC, Zijstra F, van't Hof AWJ, et al. Glucose- insulinpotassium infusion in patients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003;42:784-791.
40. Apstein CS. The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns). J Am Coll Cardiol 2003;42:792-795.
41. Nicolini F, Beghi C,Muscari C, et al. Myocardial protection in adult cardiac surgery: current options and future challenges. Eur J Cardiothorac Surg 2003;24:986-993.
42. Doenst T, Bothe W, Beyersdorf F. Therapy with insulin in cardiac surgery: controversies and possible solutions. Ann Thorac Surg 2003; 75:S721-S728.
43. Forman MB, Velasco CE. Role of adenosine in the treatment of myocardial stunning. Cardiovasc Drugs Ther 1981; 5:901-908.
44. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated review. Cardiovasc Res 2001; 52:25-39.
45. Obata T. Adenosine production and its interaction with protection of ischemic and reperfusion injury of the myocardium. Life Sci 2002; 71:2083-2103.
46. Donato M, Gelpi RJ. Adenosine and cardioprotection during reperfusion: an overview. Mol Cell Biochem 2003; 251:153-159.
47. Vinten-Johansen J, Zhao Z-Q, Corvera JS,et al. Adenosine in myocardial protection in on-pump and off-pump cardiac surgery. Ann Thorac Surg 2003; 75:S691-S699.
48. Mangano DT, Miao Y, Tudor IL,et al. Postreperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 2006; 48:206-214.49
49. Kukreja RC, Janin Y. Reperfusion injury: basic concepts and protection strategies. J Thromb Thrombolysis 1987; 4:7-24.
50. Becker LC. Do neutrophils contribute to myocardial stunning? Cardiovasc Drug Ther 1981; 5:909-913.
51. Juneau CF, Ito BR, del Balzo U,et al. Severe neutrophil depletion by leucocyte filters or cytotoxic drugs does not improve recovery of contractile function in stunned porcine myocardium. Cardiovasc Res 1983; 27:720-727.
52. Bolli R. Role of neutrophils in myocardial stunning after brief ischemia: the end of a six old controversy (1987-1993). Cardiovasc Res 1983; 27:728-730.
53. Lefer AM, Weyrich AS, Buerke M. Role of selectins, a new family of adhesion molecules, in ischemia-reperfusion injury. Cardiovasc Res 1984; 28:289-294.
54. Lefer AM. Role of selectins in myocardial ischemia-reperfusion injury. Ann Thorac Surg 1985; 60:773-777.
55. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001; 94:1133-1138.
56. Bull DA, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 2003; 75:S735-S739.
57. Garcia-Dorado D, Theroux D, Fernandez-Aviles F,et al. Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts. J Am Coll Cardiol 1987; 10:906-911.
58. Vatner SF, Patrick TA, Knight DR,et al. Effects of calcium channel blocker on responses of blood flow, function, arrhythmias, and extent of infarction following reperfusion in conscious baboons. Circ Res 1988; 62:105-115.
59. Herzog WR, Vogel RA, Schlossberg ML,et al. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int J Cardiol 1987; 59:21-27.
60. 2+ exchange in myocardial reperfusion injury in open chest dogs: relative roles during ischemia and reperfusion. Cardiovasc Res 1987; 36:337-346.
61. Siegmund B, Schlack W, Ladilov YV,et al. Halothane protects cardiomyocytes against reoxygenation-induced hypercontracture. Circulation 1987; 96:4372-4379.
62. Schlack W, Hollmann M, Stunneck J,et al. Effect of halothane on myocardial reoxygenation injury in the isolated rat heart. Br J Anaesth 1986; 76:860-867.
63. + exchange in ischemia reperfusion. Basic Res Cardiol 1986; 91:191-202.
64. Mentzer RM, Lasley RD, Jessel A,et al. Intracellular sodium hydrogen exchange inhibition and clinical myocardial protection. Ann Thorac Surg 2003; 75:S700-S708.
65. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001; 33:1897-1918.
66. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/ reperfusion injury. Cardiovasc Res 2004; 61:402-413.
67. Halonen J, Halonen P, Jä rvinen O,et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 2007; 297:1562-1567.
68. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119:1853-1866.
69. Williams TM, Harken AH. Statins for surgical patients. Ann Surg 2008; 247:30-37.
70. Biccard BM. A peri-operative statin update for noncardiac surgery. Part 1: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (nonsurgical) patients. Anaesthesia 2008; 63:52-64.
71. Biccard BM. A peri-operative statin update for noncardiac surgery. Part 2: Statin therapy for vascular surgery and peri-operative statin trial design. Anaesthesia 2008; 63:162-171.
72. Liakopoulos OJ, Choi Y-H, Haldenwang PL,et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients. Eur Heart J 2008; 29:1548-1559.
73. Kapoor AS, Kanji H, Buckingham J,et al. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 2006; 333:1149-1157.
74. Schouten O, Hoeks S, Welten GMJM,et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100:316-320.
75. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004; 61:448-460.
76. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion: a target for cardioprotection. Cardiovasc Res 2004; 61:372-385.
77. Piot C, Croisille P, Staat P,et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New Engl J Med 2008; 359:473-481.
78. Gomez L, Li B, Mewton N,et al. Inhibition of mitochondrial permeability transition pore opening: translation to patients. Cardiovasc Res 2009 [Epub ahead of print].
79. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136.
80. Gross GJ, Kersten JR, Warltier DC. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg 1989; 68:1898-1904.
81. Sommerschild HT, Kirkebøen KA. Preconditioning: endogenous defence mechanisms of the heart. Acta Anaesth Scand 2002; 46:123-137.
82. Zaugg M, Lucchinetti E, Uecker M,et al. Anaesthetics and cardiac preconditioning. Part I: Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91:551-565.
83. Deutsch E, Berger M, Kussmaul WG,et al. Adaptation to ischemia during percutaneous transluminal angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1980; 82:2044-2051.
84. Kloner RA, Shook T, Przyklenk K,et al. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation 1985; 91:37-45.
85. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1989; 99:2085-2089.
86. Ottani F, Galvani M, Ferrini D,et al. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation 1985; 91:291-297.
87. Perrault LP, Menasch́ P, Bel A,et al. Ischemic preconditioning in cardiac surgery: a word of caution. J Thorac Cardiovasc Surg 1986; 112:1378-1386.
88. Jenkins DP, Pugsley WB, Alkhulaifi AM,et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1987; 77:314-318.
89. Jacobson E, Young CJ, Aronson S,et al. The role of ischemic preconditioning during minimally invasive coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1987; 11:787-792.
90. Illes RW, Swoyer KD. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent cold blood cardioplegia. Ann Thorac Surg 1988; 65:748-752.
91. Lu EX, Chen SX, Hu TH,et al. Preconditioning enhances myocardial protection in patients undergoing open heart surgery. Thorac Cardiovasc Surg 1988; 46:28-32.
92. Lucchetti V, Caputo M, Suleiman MS,et al. Beating heart coronary revascularization without metabolic myocardial damage. Eur J Cardiothorac Surg 1988; 14:443-444.
93. Malkowski MJ, Kramer CM, Parvizi ST,et al. Transient ischemia does not limit subsequent ischemic regional dysfunction in humans: a transesophageal echocardiographic study during minimally invasive coronary artery bypass surgery. J AmColl Cardiol 1988; 31:1035-1039.
94. Laurikka J, Wu Z-K, Lisalo P,et al. Regional ischemic preconditioning enhances myocardial performance in off-pump coronary artery bypass grafting. Chest 2002; 121:1183-1189.
95. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann Thorac Surg 2003; 75:S709-S714.
96. Zaugg M, Lucchinetti E, Garcia C,et al. Anaesthetics and cardiac preconditioning. Part 2: Clinical implications. Br J Anaesth 2003; 91:566-576.
97. De Hert SG. Cardioprotection with volatile anaesthetics: clinical relevance. Curr Opin Anaesthesiol 2004; 17:57-62.
98. Tanaka K, Ludwig LM, Kersten JR,et al. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100:707-721.
99. De Hert SG, Turani F, Mathur S,et al. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg 2005; 100:1584-1593.
100. De Hert SG. The concept of anaesthetic-induced cardioprotection: clinical relevance. Best Pract Res Clin Anaesthesiol 2005; 19:445-459.
101. Weber NC, Preckel B, Schlack W. The effect of anaesthetics on the myocardium: new insights into myocardial protection. Eur J Anaesthesiology 2005; 22:647-657.
102. Fräβdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 2009 (in press).
103. Preckel B, Weber NC, Sanders RD,et al. Molecular mechanisms transducing the anesthetic, analgesic, and organ protective actions of xenon. Anesthesiology 2006; 105:187-197.
104. Fräβdorf J, Borowski A, Ebel D,et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2009; 137:1436-1442.
105. Bein B, Renner J, Caliebe D,et al. The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardiopulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anaesthesia 2008; 63:1046-1055.
106. Zhao ZQ, Corcera JS, Halkos ME,et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol 2003; 285:H579-H588.
107. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusioninduced injury. Cardiovasc Res 2006; 70:200-211.
108. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 2007; 59:418-458.
109. Staat P, Rioufol G, Piot C,et al. Postconditioning the human heart. Circulation 2005; 112:1243-1248.
110. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 2005; 65:361-367.
111. Thibault H, Piot C, Staat P,et al. Long-term benefit of postconditioning. Circulation 2008; 117:1037-1044.
112. Luo W, Li B, Lin G,et al. Postconditioning in cardiac surgery for tetralogy of Fallot. J Thorac Cardiovasc Surg 2007; 133:1373-1374.
113. Luo W, Li B, Chen R,et al. Effect of ischemic postconditioning in adult valve replacement. Eur J Cardiothorac Surg 2008; 33:203-208.
114. Schlack W, Preckel B, Barthel H,et al. Halothane reduces reperfusion injury after regional ischaemia in the rabbit heart in vivo. Br J Anaesth 1987; 79:88-96.
115. Preckel B, Schlack W, Comfere T,et al. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 1988; 81:905-912.
116. Schlack W, Preckel B, Stunneck D,et al. Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart. Br J Anaesth 1988; 81:913-919.
117. 2+ loading in intact hearts. Anesthesiology 2002; 96:125-133.
118. ATP channels. Anesth Analg 2005; 101:1590-1596.
119. Pagel PS. Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signalling. J Cardiothorac Vasc Anesth 2008; 22:753-765.
120. De Hert SG, Van der Linden PJ, Cromheecke S,et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101:299-310.
121. De Hert SG, ten Broecke PW, Mertens E,et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002; 97:42-49.
122. De Hert SG, Cromheecke S, ten Broecke PW,et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003; 99:314-323.
123. Conzen PF, Fisher S, Detter C,et al. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off pump coronary artery bypass surgery. Anesthesiology 2003; 99:826-833.
124. Bein B, Renner J, Caliebe D,et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100:610-616.
125. Guarracino F, Landoni G, Tritapepe L,et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomised controlled study. J Cardiothorac Vasc Anesth 2006; 20:477-483.
126. Kawamura T, Kadosaki M, Nora N,et al. Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2006; 20:503-508.
127. Tritapepe L, Landoni G, Guarracino F,et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 2007; 24:323-331.
128. Lucchinetti E, Hofer C, Bestmann L,et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery. Anesthesiology 2007; 106:444-457.
129. Law-Koune JD, Raynaud C, Liu N,et al. Sevoflurane-remifentanyl versus propofol-remifentanyl anesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. J Cardiothorac Vasc Anesth 2006; 20:484-492.
130. Nader ND, Li CM, Khadra WZ,et al. Anesthetic myocardial protection with sevoflurane. J Cardiothorac Vasc Anesth 2004; 18:269-274.
131. Nader ND, Karamanoukian HL, Reedy RL,et al. Inclusion of sevoflurane in cardioplegia reduces neutrophil activity during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2006; 20:57-62.
132. Corcoran TB, Engel A, Sakamoto H,et al. The effects of propofol on lipid peroxidation and inflammatory response in elective coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2004; 18:592-604.
133. Xia Z, Huang Z, Ansley DM. Large-dose propofol during cardiopulmonary bypass decreases biochemical markers of myocardial injury in coronary surgery patients: a comparison with isoflurane. Anesth Analg 2006; 103:527-532.
134. Corcoran TB, Engel A, Sakamoto H,et al. The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth 2006; 97:825-831.
135. Cromheecke S, Pepermans V, Hendrickx E,et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 2006;103:289-296.
136. Landoni G, Calabro MG, Marchetti C,et al. Desflurane versus propofol in patients undergoing mitral valve surgery. J Cardiothorac Vasc Anesth 2007; 21:672-677.
137. Fleisher LA, Newman MF, St Aubin LB,et al. Efficacy of zoniporide, an Na/H exchange ion inhibitor for reducing perioperative cardiovascular events in vascular surgery patients. J Cardiothorac Vasc Anesth 2005; 19:570-576.
138. De Hert SG, Longrois D, Yang H, Fleisher LA. Does the use of a volatile anesthetic regimen attenuate the incidence of cardiac events after vascular surgery? Acta Anaesthesiol Belg 2008; 59:19-25.
139. Landoni G, Zangrillo A, Fochi O,et al. Cardiac protection with volatile anesthetics in stenting procedures. J Cardiothorac Vasc Anesth 2008; 22:543-547.
140. De Hert SG, Van der Linden PJ, Cromheecke S,et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004; 101:9-20.
141. Cromheecke S, ten Broecke PW, Hendrickx E,et al. Atrial fibrillation after coronary surgery: can choice of the anesthetic regimen influence the incidence? Acta Anaesthesiol Belg 2005; 56:147-154.
142. Garcia C, Julier K, Bestmann L,et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 2005; 94:159-165.
143. Jakobsen CJ, Berg H, Hindsholm KB,et al. The influence of propofol versus sevoflurane anesthesia on outcome in 10 535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007; 21:664-671.
144. Yu CH, Beattie WS. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can J Anesth 2006; 53:906-918.
145. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006; 97:127-136.
146. Landoni G, Biondi-Zoccai GG, Zangrilla A,et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007; 21:502-511. (Pubitemid 47135634)
147. De Hert SG, Vlasselaers D, Barb́ R,et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009 (in press).
148. Belhomme D, Peynet J, Louzy M,et al. Evidence of preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1989; 100 (Suppl II):II340-II344.
149. Penta de Peppo A, Polisca P, Tomai F,et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg 1989; 68:112-118.
150. Tomai F, De Paulis R, Penta de Peppo A,et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. G Italian Cardiol 1989; 29:1007-1014.
151. Haroun-Bizri S, Khoury SS, Chehab IR,et al. Does isoflurane optimize myocardial protection during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 2001; 15:418-421.
152. Pouzet B, Lecharny JB, Dehoux M,et al. Is there a place for preconditioning during cardiac operations in humans? Ann Thorac Surg 2002; 73:843-848.
153. Julier K, da Silva R, Varcia C,et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded placebocontrolled, multicenter study. Anesthesiology 2003; 98:1315-1327.
154. Forlani S, Tomai F, De Paulis R,et al. Preoperative shift from glibenclamide to insulin is cardioprotective in diabetic patients undergoing coronary artery bypass surgery. J Cardiovasc Surg (Torino) 2004; 45:117-122.
155. Fellahi JL, Gue X, Philippe E,et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. Eur J Anaesthesiol 2004; 21:688-693.
156. Lee MC, Chen CH, Kuo MC,et al. Isoflurane preconditioning-induced cardio-protection in patients undergoing coronary artery bypass grafting. Eur J Anaesthesiol 2006; 23:841-847.
157. Meco M, Cirri S, Gallazzi C,et al. Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebocontrolled study. Eur J Cardiothorac Surg 2007; 32:319-325.
158. Piriou V,Mantz J, Goldfarb G,et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth 2007; 99:624-631.